OmniAb, Inc.
Candace Leslie has a diverse work experience spanning several roles and companies. Candace started their career at the North Carolina Department of Health and Human Services, where they worked as a Medical Laboratory Technologist before being promoted to Laboratory Medical Specialist and serving in that role for almost a decade. In 2019, they joined Q2 Solutions as a Laboratory Associate II for a year until 2020. Following that, they worked at Baebies as a Clinical Scientist I and later as a Clinical Scientist II from 2020 to 2021. In 2021, Candace joined Icagen as a Scientist until 2022. Currently, they are working at OmniAb, Inc. as a Scientist from November 2022 onwards.
Candace Leslie earned their Bachelor of Science (B.S.) degree in Biology from North Carolina Central University, completing their studies from 1997 to 2001.
This person is not in any offices
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.